Nonvenereal Syphilis Treatment Market Trends

  • Report ID: 3569
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Nonvenereal Syphilis Treatment Market Trends

Growth Drivers

  • Rising Prevalence of Infectious Diseases – diseases such as syphilis, bejel, pinta, and yaws are rare but it’s increasing prevalence worldwide is leading to surging investments in its prevention & treatment which is expected to boost the growth of the nonvenereal syphilis treatment market in the projected years. Centers for Disease Control and Prevention unveiled that in 2019 around 129,813 cases of all stages of syphilis, were reported worldwide.
  • Growing Burden of Incidences Associated with Bacterial Pathogens – as per a study nearly 7·7 million deaths globally were associated with 33 different bacterial pathogens (both resistant and susceptible to antimicrobials), which comprised nearly 13·6% of all global deaths and 56·2% of all sepsis-related deaths in 2019. Owing to these widespread concerns about bacterial pathogens, the government of various countries is joining hands to eradicate diseases caused by different pathogens, which will indirectly result in improved rapid diagnostic tests to detect syphilis and nonvenereal syphilis and its treatment.
  • Rising Cases of Diseases Caused by Treponema species – diseases such as yaws are gaining prevalence, mostly in children. It is observed that nearly 75–80% of people affected by yaws are children under 15 years of age with peak incidences occurring in children aged 6–10 years. Hence, this has elevated research on medications and treatment of diseases caused by Treponema species that also cause bejel, and pinta and is morphologically and serologically indistinguishable from the agent syphilis This, as a result, is expected to propel the market growth in the projected years.
  • Strategies to Eradicate Neglected Tropical Diseases – World Health Organization (WHO) has drawn a 2021-2030 roadmap for the eradication of rare tropical diseases which include syphilis, yaws, and bejel to attain the Sustainable Development Goals. The roadmap was prepared through an extensive global consultation pursuant to decision EB146(9) of the Executive Board at WHO’s 146th session in February 2020.

Challenges

  • Persistent Challenges in the Diagnostic Landscape and Testing Models – are hindering global nonvenereal syphilis control efforts. The challenges in the diagnosis of active syphilis infection, bejel, yaws, and pinta diseases owing to insufficient research and development in key areas and the present technological, individual, and structural barriers in access to nonvenereal syphilis testing is a major restraining factor of nonvenereal syphilis treatment market.
  • Lack of Highly Trained Laboratory Technologists and Complex/ Expensive Laboratory Instruments
  • Lack of Healthcare Infrastructure

Nonvenereal Syphilis Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

8.9%

Base Year Market Size (2023)

USD 304.92 Million

Forecast Year Market Size (2036)

USD 923.74 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3569
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nonvenereal syphilis treatment is assessed at USD 329.34 Million.

The nonvenereal syphilis treatment market size was over USD 304.92 Million in 2023 and is expected to reach USD 923.74 Million by the end of 2036, growing at around 8.9% CAGR during the forecast period i.e., between 2024-2036. The rising cases of bejel as well as the increasing augmentation of infectious diseases are the major growth factors driving the growth of the market.

Middle East and Africa is likely to dominate majority industry share by 2036, attributed to existence of nonvenereal syphilis in regions of West Africa, the Mediterranean, and the Sahara propelled by lack of sanitization as well as the hot and humid climate.

Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample